Linzatin M 500 Tablet contains Metformin 500mg + Linagliptin 5mg, a dual-action oral antidiabetic therapy designed for type 2 diabetes management. Metformin enhances insulin sensitivity and reduces hepatic glucose production, while Linagliptin, a DPP-4 inhibitor, increases incretin hormones to stimulate insulin release and reduce glucagon secretion.
This tablet is part of the diabetes care segment, offering a convenient fixed-dose combination that targets multiple mechanisms of glucose control. Its formulation reduces pill burden and helps patients maintain consistent glycemic levels.
Linzatin M 500 Tablet is widely prescribed by endocrinologists, general physicians, hospitals, and clinics, making it a high-demand product for PCD pharma franchise and B2B distribution. Its dual-action mechanism ensures effective glycemic control, patient adherence, and repeat prescriptions.
For PCD pharma franchise and B2B partners, Linzatin M 500 Tablet represents a profitable and high-demand opportunity. With steady demand from hospitals, clinics, and retail pharmacies, it is ideal for domestic distribution, export, and third-party manufacturing, ensuring sustainable business growth and attractive margins.